Clinical Validation of Histotype Px Colorectal in U.S. Patients to be Presented at ESMO AI & Digital Oncology Congress 2025
OSLO – November 12, 2025 – DoMore Diagnostics, a leader in AI and deep-learning for precision medicine for cancer, is pleased to announce that a poster with clinical data from The Ohio State University Comprehensive Cancer Center (OSUCCC) validating our digital biomarker Histotype Px® Colorectal (Histotype Px), will be presented at the ESMO AI & Digital Oncology Congress 2025 in Berlin.
The study, titled “External validation of Histotype Px for risk stratification in a US patient cohort” (Poster 52P), demonstrates how AI-driven analysis of H&E tumor images by Histotype Px can enhance prognostic precision and potentially guide adjuvant chemotherapy (ACT) treatment decisions in patients with stage II/III colorectal cancer (CRC).
Key findings:
The retrospective-prospective study included 503 patients with stage II/III colon adenocarcinoma from Ohio State University, diagnosed between 2011 and 2024.
Histotype Px® Colorectal was a significant predictor of 5-year cancer-specific survival (CSS) and time to recurrence (TTR), with a hazard ratio of 8.7 (CSS) and 4.5 (TTR) for high vs low risk patients.
Patients classified as low-risk by Histotype Px had high 5-year cancer specific survival rates of 96% for stage II and 91% for stage III.
41% of stage III patients were classified as low risk by Histotype Px, suggesting that many patients currently receiving adjuvant chemotherapy may safely avoid this toxic treatment.
Conversely, patients identified as high-risk showed markedly worse outcomes, indicating potential benefit from treatment escalation.
“AI-based digital biomarkers like Histotype Px® have the potential to transform oncology by enabling more personalized and evidence-based treatment decisions,” said Prof. Giovanni Lujan, lead author and gastrointestinal pathologist at The Ohio State University Wexner Medical Center. “This external validation confirms its prognostic robustness and clinical utility in a U.S. patient cohort, and future studies will explore prediction of ACT benefit by Histotype Px in this patient population.”
Torbjørn Furuseth, CEO & Co-Founder of DoMore Diagnostics, added:
“We are proud to collaborate with Ohio State University in validating Histotype Px. These results strengthens the previously published findings in U.S. patients and reinforce how our AI-based digital biomarker can decode valuable prognostic information hidden in routine H&E histology slides, ultimately improving cancer care and patient outcomes.”
The poster will be presented on Wednesday, November 12, 2025, 14:45-15:45 CET at the ESMO AI & Digital Oncology Congress in Berlin, highlighting how Histotype Px® Colorectal can support more precise and individualized adjuvant therapy decisions in colorectal cancer. Institute for Cancer Genetics and Informatics at Oslo University Hospital was also part of the collaboration.
Link to Abstract: https://cslide.ctimeetingtech.com/coasis_21451/attendee/confcal/show/session/3
This study was supported by an EIC Accelerator grant awarded to DoMore Diagnostics from the European Commission under Horizon Europe.
Poster (to be uploaded following poster session):
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
DoMore Diagnostics has received funding from the European Innovation Council (EIC) Accelerator program.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com